Essential thrombocythemia as an initial presentation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with complete response to the bortezomib, cyclophosphamide, dexamethasone regimen: a case report
Open Access
- 1 July 2025
- journal article
- case report
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 1-6
Abstract
Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome is a rare paraneoplastic disorder often presenting with atypical manifestations, making diagnosis challenging. This case is novel due to the rare presentation of essential thrombocythemia as the initial manifestation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome. Furthermore, it highlights the remarkable therapeutic response, achieving a complete remission following treatment with the bortezomib, cyclophosphamide, dexamethasone regimen, underscoring this combination therapy’s efficacy in managing such complex cases. A 65-year-old Iranian woman presented with fatigue, headache, and thrombocytosis, leading to a diagnosis of essential thrombocythemia. Over time, her condition progressed with the development of neuropathy and persistence of thrombocytosis, which warranted further investigation. Imaging revealed multiple lymphadenopathies, sclerotic bone lesions, and ascitic fluid, raising suspicion for a plasma cell dyscrasia. Bone marrow biopsy, lymph node biopsy, and elevated vascular endothelial growth factor levels confirmed the diagnosis of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome. The patient was treated with bortezomib, cyclophosphamide, dexamethasone chemotherapy regimen, resulting in complete symptom relief, normalization of the complete blood count, and significant improvement in imaging findings. This case highlights the need to recognize atypical polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome presentations, such as essential thrombocythemia, for timely diagnosis and underscores the bortezomib, cyclophosphamide, dexamethasone regimen’s efficacy in achieving complete remission.Keywords
This publication has 27 references indexed in Scilit:
- POEMS syndrome: Update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patientsAmerican Journal of Hematology, 2021
- Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisOncoImmunology, 2021
- POEMS Syndrome: 2019 Update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2019
- Ki-67: more than a proliferation markerChromosoma, 2018
- Multiple angiogenetic factors are upregulated in POEMS syndromeAnnals of Hematology, 2012
- Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesisBrain, 2005
- The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative diseaseCancer, 2002
- The expression and function of CD3 and CD5 in patients with primary sjögren's syndromeArthritis & Rheumatism, 1989
- Comparison of Cytokeratin Expression in Primary and Metastatic Carcinomas: Diagnostic Application in Surgical PathologyAmerican Journal of Clinical Pathology, 1987